Reduced CDH16 expression is linked to poor prognosis in clear cell renal cell carcinoma 16-Reference-Cited by-同舟云学术

Reduced CDH16 expression is linked to poor prognosis in clear cell renal cell carcinoma 16

Published:2022-07 Issue:7 Volume:40 Page:348.e1-348.e8
ISSN:1078-1439
Container-title:Urologic Oncology: Seminars and Original Investigations
language:en
Short-container-title:Urologic Oncology: Seminars and Original Investigations

Author:

Lennartz Maximilian,Csomós Henrietta,Bernreuther Christian,Büscheck Franziska,Fraune Christoph,Simon Ronald^ORCID,Sauter Guido,Steurer Stefan,Eichenauer Till,Dahlem Roland,Fisch Margit,Riechardt Silke,Rink Michael,Minner Sarah,Höflmayer Doris

Publisher

Elsevier BV

Subject

Urology,Oncology

Reference28 articles.

1. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J Clin,2021

2. Pembrolizumab plus Axitinib versus sunitinib for advanced renal-cell carcinoma;Rini;N Engl J Med,2019

3. Nivolumab plus Ipilimumab versus sunitinib in advanced renal-cell carcinoma;Motzer;N Engl J Med,2018

4. Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the alliance A031203 CABOSUN trial;Choueiri;J Clin Oncol,2017

5. Prevalence, disease-free, and overall survival of contemporary patients with renal cell carcinoma eligible for adjuvant checkpoint inhibitor trials;Marconi;Clin Genitourin Cancer,2021

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cadherin-16 (CDH16) immunohistochemistry: a useful diagnostic tool for renal cell carcinoma and papillary carcinomas of the thyroid;Scientific Reports;2023-08-09